Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis

Drug Metabolism and Disposition

Volumn 27, Issue 7, 1999, Pages 816-820

  Sparreboom, Alex ^a   De Jonge, Maja J A ^a   Punt, Cornelis J A ^b   Loos, Walter J ^a   Nooter, Kees ^a   Stoter, Gerrit ^a   Porro, Maria Grazia ^c   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; CARBOXYLIC ACID; LACTONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033033055     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chabot GG (1995) Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 36:463-472.
2. Creemers GJ, Lund B and Verweij J (1994) Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96.
3. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton M, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W and Grem J (1996) Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244.
4. De Jonge MJA, Punt CJA, Gelderblom AH, Loos WJ, Van Beurden V, Planting AST, Van der Burg MEL, Van Maanen LWGM, Dallaire BK, Verweij J, Wagener DJT and Sparreboom A (1999a) Phase I and pharmacologic study of oral [PEG1000] 9-aminocamptothecin in adult patients with solid tumors. J Clin Oncol, in press.
5. De Jonge MJA, Verweij J, Loos WJ, Dallaire BK and Sparreboom A (1999b) Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva. Clin Pharmacol Ther 65:491-499.
6. De Souza PL, Cooper MR, Imondi AR and Myers CE (1997) 9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res 3:287-294.
7. Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G and Kufe DW (1998) Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 4:317-324.
8. Gerrits CJH, De Jonge MJA, Schellens JHM, Stoter G and Verweij J (1997) Topoisomerase-I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962.
9. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice with 20-(S)-camptothecin. Cancer Res 51:3052-3055.
10. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R and Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Wash DC) 246:1046-1048.
11. Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB and Piantadosi S (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Phamacol 42:118-127.
12. Hertzberg RP, Caranfa MJ and Hecht SM (1989a) On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28:4629-4638.
13. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattem MR, Mong S, Bartus JO, Johnson RK and Kingsbury WD (1989b) Modification of the hydroxy-lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32:715-721.
14. Hsiang Y, Hertzberg R, Hecht S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878.
15. Hsiang Y, Lihou M and Liu L (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082.
16. Loos WJ, Sparreboom A, Verweij J, Nooter K, Stoter G and Schellens JHM (1997) Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. J Chromatogr 694:435-441.
17. Mathijssen RHJ, Van Alphen RJ, De Jonge MJA, Verweij J, De Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G and Sparreboom A (1999) Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin. Anti-Cancer Drugs 10:9-16.
18. Mick R, Gupta E, Vokes EE and Ratain MJ (1996) Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019.
19. Minami H, Beijnen JH, Verweij J and Ratain MJ (1996) Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res 2:43-46.
20. Nakashima H, Lieberman R, Karato A, Arioka H, Ohmatsu H, Nomura N, Shiraishi J, Tamura T, Eguchi K, Shinkai T, Sasaki Y, Yamamoto N, Hukuda M, Oshita F, Ohe Y and Saijo N (1995) Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): Implication for area under the concentration-time curve monitoring. Ther Drug Monit 17:221-229.
21. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR and Giovanella BC (1993) Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53:1577-1582.
22. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ, Stehlin JS and Giovanella BC (1992) Inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987.
23. Pastori A, Farao M, Geroni C, Porro MG and Grandi M (1997) Antitumor activity of 9-aminocamptothecin (9ac) by s.c. and oral route (Abstract). Proc Am Assoc Cancer Res 38:18.
24. Potmesil M (1994) Camptothecins from bench research to hospital wards. Cancer Res 54:1431-1439.
25. Potmesil M, Liebes L, Drygas I, Sekiya S, Morse L, Kozielski AJ, Wall ME, Wani MC, Stehlin JS and Giovanella BC (1995) Pharmacodynamics/pharmacokinetics of intragastric (IG) camptothecin analogs in a human-cancer xenograft model (Abstract). Proc Am Assoc Cancer Res 36:445.
26. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D and Kufe D (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276.
27. Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Sekine I, Miyata Y and Saijo N (1995) A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38. Jpn J Cancer Res 86:117-123.
28. Sheiner LB and Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.
29. Sparreboom A, De Jonge MJA, Punt CJA, Nooter K, Loos WJ, Porro MG and Verweij J (1998) Pharmacokinetics and bioavailability of oral 9-aminocamptothecin in adult patients with solid tumors. Clin Cancer Res 4:1915-1919.
30. Takimoto CH and Arbuck SG (1996) The camptothecins, in Cancer Chemotherapy and Biotherapy (Chapner BA and Longo DL eds) pp 463-488, Lippincott-Raven Publishers, Philadelphia.
31. Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ and Grem JL (1997) Pharmacokinetics and pharmacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492-1501.
32. Van Warmerdam LCJ, Ten Bokkel Huinink WW, Maes RAA and Beijnen JH (1994a) Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 120:427-433.
33. Van Warmerdam LCJ, Verweij J, Rosing H, Schellens JHM, Maes RAA and Beijnen JH (1994b) Limited sampling models for topotecan pharmacokinetics. Ann Oncol 5:259-264.
34. Yamamoto N, Tamura T, Karato A, Uenaka K, Eguchi K, Shinkai T, Ohe Y, Oshita F, Arioka H, Nakashima H, Shiraishi J-I, Fukuda M, Higuchi S and Saijo N (1994) CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 85:972-977.
35. Yamamoto N, Tamura T, Nishiwaki Y, Kurita Y, Kawakami Y, Abe S, Nakabayashi T, Suzuki S, Matsuda T, Hayashi I, Takahashi T and Saijo N (1997) Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II study. Clin Cancer Res 3:1087-1092.